StemRIM Future Growth

Future criteria checks 1/6

StemRIM is forecast to grow earnings and revenue by 6.5% and 10.7% per annum respectively. EPS is expected to grow by 4% per annum. Return on equity is forecast to be -38.5% in 3 years.

Key information

6.5%

Earnings growth rate

4.0%

EPS growth rate

Biotechs earnings growth	9.7%
Revenue growth rate	10.7%
Future return on equity	-38.5%
Analyst coverage	Low
Last updated	11 Sep 2024

Recent future growth updates

Recent updates

StemRIM (TSE:4599) Is In A Strong Position To Grow Its Business

Oct 04

StemRIM's (TSE:4599) Earnings Seem To Be Promising

Mar 20

Earnings and Revenue Growth Forecasts

TSE:4599 - Analysts future estimates and past financials data (JPY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
7/31/2027	540	-1,486	-1,325	-1,325	1
7/31/2026	N/A	-1,980	-1,835	-1,835	1
7/31/2025	1,000	-1,000	-824	-825	1
7/31/2024	N/A	-2,022	-1,885	-1,881	N/A
4/30/2024	N/A	-2,131	N/A	N/A	N/A
1/31/2024	2,350	179	608	610	N/A
10/31/2023	2,350	214	N/A	N/A	N/A
7/31/2023	2,350	168	1,135	1,135	N/A
4/30/2023	2,350	332	N/A	N/A	N/A
1/31/2023	N/A	-1,957	-1,428	-1,428	N/A
10/31/2022	N/A	-1,971	N/A	N/A	N/A
7/31/2022	22	-1,948	-1,404	-1,404	N/A
4/30/2022	1,212	-788	N/A	N/A	N/A
1/31/2022	1,212	-813	-356	-295	N/A
10/31/2021	1,212	-811	N/A	N/A	N/A
7/31/2021	1,400	-582	-608	-519	N/A
4/30/2021	1,910	-501	N/A	N/A	N/A
1/31/2021	2,310	89	14	191	N/A
10/31/2020	2,310	358	N/A	N/A	N/A
7/31/2020	2,100	347	423	575	N/A
4/30/2020	400	-662	N/A	N/A	N/A
7/31/2019	100	-721	-783	-777	N/A
7/31/2018	200	-323	N/A	N/A	N/A
7/31/2017	300	-123	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4599 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 4599 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 4599 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 4599's revenue (10.7% per year) is forecast to grow faster than the JP market (4.1% per year).

High Growth Revenue: 4599's revenue (10.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 4599 is forecast to be unprofitable in 3 years.

StemRIM Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Price target decreased by 25% to JP¥900

StemRIM Provides Earnings Guidance for the Year Ending July 31, 2023

Price target increased to JP¥1,240

Price target increased to JP¥1,400

Price target increased to JP¥1,000

Price target decreased to JP¥1,250

Recent updates

StemRIM to Report Q1, 2025 Results on Dec 11, 2024

StemRIM (TSE:4599) Is In A Strong Position To Grow Its Business

StemRIM, Annual General Meeting, Oct 30, 2024

StemRIM to Report Fiscal Year 2024 Results on Sep 11, 2024

New major risk - Revenue size

StemRIM to Report Q3, 2024 Results on Jun 12, 2024

StemRIM's (TSE:4599) Earnings Seem To Be Promising

Price target decreased by 25% to JP¥900

StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy

StemRIM Inc. Announces Patent Registration (Russia) for the Use of the HMGB1 Fragment Peptide, as an Additional Therapeutic Indication of Cartilage Disorders

StemRIM to Report Q2, 2024 Results on Mar 13, 2024

StemRIM to Report Q1, 2024 Results on Dec 13, 2023

StemRIM, Annual General Meeting, Oct 25, 2023

StemRIM Announces Patent Registration (China) for the Use of Redasemtide as an Additional Treatment for Cardiomyopathy and Old Myocardial Infarction

StemRIM Inc. Announces the First Administration of Global Late Phase 2 Clinical Trials for Redasemtide Targeting Acute Ischemic Stroke (Japan)

StemRIM Inc. Announces Commencement of Global Late Phase 2 Clinical Trial for Redasemtide in Patients with Acute Ischemic Stroke in the Europe and China

StemRIM to Report Fiscal Year 2023 Results on Sep 13, 2023

StemRIM Provides Earnings Guidance for the Year Ending July 31, 2023

Third quarter 2023 earnings released: EPS: JP¥31.50 (vs JP¥8.31 loss in 3Q 2022)

StemRIM to Report Q2, 2023 Results on Mar 08, 2023

Price target increased to JP¥1,240

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: JP¥32.91 loss per share (vs JP¥10.02 loss in FY 2021)

StemRIM to Report Q1, 2023 Results on Dec 14, 2022

StemRIM, Annual General Meeting, Oct 26, 2022

Full year 2022 earnings released: JP¥32.91 loss per share (vs JP¥10.02 loss in FY 2021)

StemRIM to Report Fiscal Year 2022 Results on Sep 08, 2022

Third quarter 2022 earnings released: JP¥8.31 loss per share (vs JP¥8.82 loss in 3Q 2021)

Price target increased to JP¥1,400

StemRIM to Report Q2, 2022 Results on Mar 10, 2022

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: JP¥10.02 loss per share (vs JP¥6.43 profit in FY 2020)

Price target increased to JP¥1,000

Full year 2021 earnings released: JP¥10.02 loss per share (vs JP¥6.43 profit in FY 2020)

Price target decreased to JP¥1,250

New 90-day high: JP¥830

StemRIM to Report Q2, 2021 Results on Mar 11, 2021

New 90-day low: JP¥624

New 90-day low: JP¥751

StemRIM to Report Fiscal Year 2020 Results on Sep 11, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies